News

The double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial showed a reduction in cardiovascular death, myocardial infarction and stroke in patients with ACS, compared

The trial, TR701-113 will study the possibility of switching tedizolid phosphate as a once-daily intravenous (IV) infusion to once-daily oral therapy in ABSSSI patients. The 113 study in

The equity funding package comprising private placement will raise a total of $1,951,369.33 by way of a placement of Allied Healthcare shares to investors and related parties of

Selumetinib, a small molecule MEK inhibitor, is an anti-cancer drug in Phase 2 development in a range of tumors. It was licensed from Array to AstraZeneca. The study

Scarlett has an experience of over 25 years in the pharmaceutical and biotechnology industry. Previously, he served as President and Chief Executive Officer of Proteolix, a biotechnology company

Nanotherapeutics will conduct studies to develop an improved formulation of diethylenetriaminepentaacetate (DTPA) and improve manufacturing its processes. DTPA can bind radioactive molecules to help the body remove them

Linaclotide is a guanylate cyclase type-C (GC-C) agonist. The company provided its efficacy and safety data from a Phase 3 program comprising two double-blind placebo-controlled trials. Over 1,600

AstraZeneca has filed a lawsuit against Handa for submitting an Abbreviated New Drug Application (ANDA) for a generic version of SEROQUEL XR to the US Food and Drug

This technology determines the efficacy of dynamic cellular reaction against target compounds within one hour after the compound is added. According to the comany, the method will contribute